

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Assessment of E & C vitamins effects on oxidative stress biomarkers, biochemical parameters, Depression, anxiety and stress in workers exposed to noise, cement dust and silica in SHIRAZ cement plant.

#### Protocol summary

##### Study aim

The aim is determine the effect of E and C vitamins intervention on oxidative stress biomarkers, biochemical parameters, Anxiety, depression and stress in workers who exposure to cement dust.

##### Design

Clinical trial study with 2 group include main intervention group that use E and C vitamins and control intervention group that use placebo, Stratified randomized and double blind with parallel group and include 80 participants

##### Settings and conduct

Cement dust has many harmful effects on health, So we do this study in Fars cement plant in Shiraz, after choice participant by stratified randomized, Blood sampling perform at the beginning of the work shift at 7 morning. And assessing the oxidative stress level, biochemical parameters before intervention, Also DASS questionnaire filled out. Then vitamins and placebos gives to participants every day along 2 month by our assistant . Researcher and participants not aware of the process of intervention. After two month we will do blood sampling again and will compares the level of oxidative stress, biochemical parameters, with the amount of them before intervention.

##### Participants/Inclusion and exclusion criteria

Workers with any underlying disease including diabetes, hypertension, heart disease, and kidney disease Workers who take a particular drug or vitamins that has effect on intervention as well as those with less than 5 years job experience Workers who singe a written informed consent

##### Intervention groups

The main intervention group are participants that use E and C vitamins, And control intervention group are participants that use placebo

##### Main outcome variables

malondialdehyde, total antioxidant capacity, superoxide dismutase, catalase, silica, alkaline phosphatase, alanine transaminase, aspartate transaminase, high density lipid, low density lipid, triglyceride, total bilirubin, glucose, albumin, creatinine, Anxiety, depression and stress

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200322046834N1**

Registration date: **2020-04-23, 1399/02/04**

Registration timing: **prospective**

Last update: **2020-04-23, 1399/02/04**

Update count: **0**

##### Registration date

2020-04-23, 1399/02/04

##### Registrant information

##### Name

Faezeh Darabi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 83 3837 2107

##### Email address

faeze.darabi@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-07-20, 1399/04/30

##### Expected recruitment end date

2020-09-20, 1399/06/30

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Assessment of E & C vitamins effects on oxidative stress biomarkers, biochemical parameters, Depression, anxiety and stress in workers exposed to noise, cement dust and silica in SHIRAZ cement plant.

**Public title**

Assessment of vitamin C and E effect in prevent of disease in workers

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Have at least 5 years job experience sign the written informed consent

**Exclusion criteria:**

Workers have underlying disease including diabetes, heart disease, kidney disease, gastrointestinal discomfort, and hypertension Using particular drug or vitamins that effect on our intervention

**Age**

From **20 years** old to **50 years** old

**Gender**

Male

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **80**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

In this study, because the cement plant consisted of different sections, We chose the stratified randomization method, In this study we have seven units in cement plant and With regard to the number of people in each section we chose our community to participate in this study. After stratified randomization and selection of the total sample size (80) select workers we use flip the coin method to choose participants for intervention and the group of vitamins intervention and placebo intervention will be determined.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study we will provide placebo tablet similar to the original tablets content C and E vitamins. Then vitamins and placebos will give to participants by assistant, researcher and participants will not aware of content of

tablets.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Shiraz University of Medical Sciences Ethics Committee

**Street address**

No. 11, Second Alley, Second 16 meters Street, Shahid Najafi Quarter, Kermanshah, Iran

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6719683515

**Approval date**

2019-05-07, 1398/02/17

**Ethics committee reference number**

IR.SUMS.REC.1398.386

**Health conditions studied****1****Description of health condition studied**

The participant of this study are workers who exposed to harmful agent include cement dust, silica, noise in cement plant

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Malondialdehyde

**Timepoint**

malondialdehyde measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Malondialdehyde will measure based on its reaction with thiobarbituric acid reactive substances and will determine by using fluorimetry.

**2****Description**

Total antioxidant capacity

**Timepoint**

Total antioxidant capacity measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Total antioxidant capacity will be measured by ferric reducing ability in plasma method.

**3**

**Description**

Superoxide dismutase

**Timepoint**

Superoxide dismutase measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Activity of superoxide dismutase will measure by superoxide dismutase kit.

**4**

**Description**

Catalase

**Timepoint**

Catalase measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Catalase enzyme will determine by catalase kit

**5**

**Description**

Alkaline phosphatase

**Timepoint**

Alkaline phosphatase measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Alkaline phosphatase will be measured by using standard kit and auto analyzer system.

**6**

**Description**

Alanine transaminase

**Timepoint**

Alanine transaminase measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

alanine transaminase will be measured by using standard kit and auto analyzer system.

**7**

**Description**

Aspartate transaminase

**Timepoint**

Aspartate transaminase measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Aspartate transaminase will be measured by using standard kit and auto analyzer system.

**8**

**Description**

High density lipid

**Timepoint**

High density lipid measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

High density lipid will be measured by using standard kit and auto analyzer system.

**9**

**Description**

Low density lipid

**Timepoint**

Low density lipid measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Low density lipid will be measured by using standard kit and auto analyzer system.

**10**

**Description**

Triglyceride

**Timepoint**

Triglyceride measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Triglyceride will be measured by using standard kit and auto analyzer system.

**11**

**Description**

Total bilirubin

**Timepoint**

Total bilirubin measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Total bilirubin will be measured by using standard kit and auto analyzer system.

**12**

**Description**

Glucose

**Timepoint**

Glucose measurement will be performed One day before the intervention, And one day after the intervention.

**Method of measurement**

Glucose will be measured by using standard kit and auto analyzer system.

### **13**

#### **Description**

Albumin

#### **Timepoint**

Albumin measurement will be performed One day before the intervention, And one day after the intervention.

#### **Method of measurement**

Albumin will be measured by using standard kit and auto analyzer system.

### **14**

#### **Description**

Creatinine

#### **Timepoint**

Creatinine measurement will be performed One day before the intervention, And one day after the intervention.

#### **Method of measurement**

creatinine will be measured by using standard kit and auto analyzer system.

### **15**

#### **Description**

Cholesterol

#### **Timepoint**

Cholesterol measurement will be performed One day before the intervention, And one day after the intervention.

#### **Method of measurement**

Cholesterol will be measured by using standard kit and auto analyzer system.

### **16**

#### **Description**

Depression

#### **Timepoint**

The DASS-21 questionnaire will be filled by the participants one day before intervention and one day after intervention.

#### **Method of measurement**

Participants' depression will be obtained by using the total score obtained from filling out the questions.

### **17**

#### **Description**

Stress

#### **Timepoint**

The DASS-21 questionnaire will be filled by the participants one day before intervention and one day after intervention

#### **Method of measurement**

Participants' stress will be obtained by using the total score obtained from filling out the questions.

### **18**

#### **Description**

Anxiety

#### **Timepoint**

The DASS-21 questionnaire will be filled by the participants one day before intervention and one day after intervention.

#### **Method of measurement**

Participants' anxiety will be obtained by using the total score obtained from filling out the questions.

### **Secondary outcomes**

empty

### **Intervention groups**

#### **1**

##### **Description**

Intervention group: This group will 40 participants that use vitamin E and vitamin C, The doses of them by arrangement are 400 IU and 500mg. They will use these vitamins for two months and our assistant give it to them every day after lunch. these vitamins product by Dena Pharmaceutical Company.

##### **Category**

Prevention

#### **2**

##### **Description**

Control group: This group will 40 participants that use placebo for two months and our assistant give it to them every day after lunch. The content of them is sugar. these placebos product by Dena Pharmaceutical Company.

##### **Category**

Placebo

### **Recruitment centers**

#### **1**

##### **Recruitment center**

###### **Name of recruitment center**

Fars cement plant

###### **Full name of responsible person**

Alireza Bostanian

###### **Street address**

No. 45, Hedayat Street, Postchi Blvd

###### **City**

Shiraz

###### **Province**

Fars

###### **Postal code**

7134953884

###### **Phone**

+98 71 3822 8644

###### **Email**

faeze.darabi@gmail.com

###### **Web page address**

### **Sponsors / Funding sources**

## 1

### Sponsor

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Kamyar Zomorodian

**Street address**

school of health, front of the Bargh club, Razi Blvd,  
Shiraz, Iran

**City**

Shiraz

**Province**

Fars

**Postal code**

7134953884

**Phone**

+98 71 3235 1268

**Email**

faeze.darabi@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shiraz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Faeze Darabi

**Position**

Student

**Latest degree**

Master

**Other areas of specialty/work**

Occupational Health

**Street address**

school of health, front of the Bargh club, Razi Blvd,  
Shiraz, Iran

**City**

Shiraz

**Province**

Fars

**Postal code**

6719683515

**Phone**

+98 83 3837 2107

**Email**

faeze.darabi@gmail.com

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Faezeh Darabi

**Position**

Student

**Latest degree**

Master

**Other areas of specialty/work**

Occupational Health

**Street address**

No 45. Hedayat Street, Soratgar Blvd.

**City**

Shiraz

**Province**

Fars

**Postal code**

7134953884

**Phone**

+98 71 3235 1268

**Email**

faeze.darabi@gmail.com

### Person responsible for updating data

**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Faezeh Darabi

**Position**

Master

**Latest degree**

Master

**Other areas of specialty/work**

Occupational Health

**Street address**

No. 11. Second Alley. Second 16 meters Street.  
Shahid Najafi Quarter. Kermanshah. Iran

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6719683515

**Phone**

+98 83 3837 2107

**Fax****Email**

faeze.darabi@gmail.com

### Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Not applicable

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

The data about participants such as main variable can be share after unrecognizable our participants

**When the data will become available and for how long**

The time to accesses the information will be four month

after publish the results

**To whom data/document is available**

The information will be available to researchers every where, And we will give the information to people who working in industry.

**Under which criteria data/document could be used**

After do statistical analyses on our information we publish the data in an article, So it will be available for every one.

**From where data/document is obtainable**

Individuals can access the article by searching the subjects name that we express, And the article will include the editors email address to answer questions.

**What processes are involved for a request to access data/document**

After publish the article editor will be online to answer your request, And the process of doing this project and publish article about it has need 8 month nearly

**Comments**